嵌合抗原受体修饰的T细胞免疫治疗研究进展

Research progress of application of immunotherapy by chimeric antigen receptor-engineered T cells

嵌合抗原受体修饰的T细胞（CAR—T细胞）是将单链抗体技术和T细胞活化基序结合应用的一种新的免疫治疗技术，具有特异、持久的肿瘤杀伤效应，在B淋巴细胞白血病、B淋巴瘤及实体瘤的临床试验中取得了令人震惊的效果，但也存在着脱靶效应、细胞因子释放综合征、移植物抗宿主病等潜在的风险。文章就CAR—T细胞原理、优势、临床应用等方面进行简要综述。

The technique of chimeric antigen receptor-engineered T cells （CAR-T） is combined single chain antibody and T-cell activation modification and has specific and durable killing effect on tumors. It had achieved stunning results on clinical trials of B lymphocytic leukemias, B lymphomas and solid tumors. Meanwhile it also had potential risk on the off target effects, cytokine release syndrome, graft versus host disease and so on. This paper briefly reviews the principal of CAR-T cellular mechanism, advantages and clinical applications.